Want to see HK:6160 full AI Analyst Report?
6160 Stock Chart & Stats
HK$226.00
HK$0.50(0.25%)
At close: 4:00 PM EDT
HK$226.00
HK$0.50(0.25%)
Day’s Range― - ―
52-Week RangeHK$153.00 - HK$235.60
Previous CloseN/A
Volume2.70M
Average Volume (3M)4.32M
Market Cap
HK$326.66B
Enterprise ValueHK$231.34K
Total Cash (Recent Filing)HK$5.10B
Total Debt (Recent Filing)HK$1.14B
Price to Earnings (P/E)61.9
Beta0.86
Next Earnings
Nov 05, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding1,427,230,000
10 Day Avg. Volume3,320,136
30 Day Avg. Volume4,321,187
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$271.37Price Target Upside20.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)4.47
Revenue Forecast (FY)HK$52.95B
Bulls Say, Bears Say
Bulls Say
Profitability And MarginsThe return to profitability, combined with consistently very high gross margins, indicates stronger earnings economics and meaningful product value. If maintained, this margin structure can support reinvestment in oncology research, commercialization, and expansion while improving resilience over the next several quarters.
Cash GenerationStrong operating and free cash flow gives BeOne internal funding for clinical development, regulatory activity, and commercial growth without relying solely on external capital. Free cash flow equal to about 85% of net income also supports the credibility and durability of the recent earnings recovery.
Regulatory And Clinical ProgressThe FDA approval converts positive Phase 3 evidence into an expanded commercial treatment opportunity in first-line HER2-positive gastroesophageal cancer. The demonstrated survival advantage strengthens the oncology portfolio, supports adoption potential, and can extend the company’s durable revenue base.
Bears Say
Slowing Revenue GrowthRevenue growth has decelerated despite the return to profitability, making future earnings expansion more dependent on execution, new indications, and sustained product uptake. Slower top-line growth can limit operating leverage and makes it harder for the company to compound results at its historical pace.
Cash-flow ConsistencyCurrent cash generation is encouraging, but the recent history of materially negative cash flows shows that consistency has not yet been fully established. Operating cash flow below net income also points to timing or working-capital effects, which could make internally funded investment less predictable.
Rising LeverageThe increase in debt relative to equity reduces financial flexibility compared with the prior year, even though current leverage remains moderate and equity has built over time. If earnings volatility returns, higher leverage could constrain investment choices and increase pressure on future cash allocation.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$153.00 and its highest was HK$235.60 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$326.66B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 58 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on Aug 05, 2026. The company reported HK$1.237 earnings per share for the quarter, beating the consensus estimate of HK$1.001 by HK$0.236.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 1.15.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,427,230,000 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$1.237 in its last earnings report, beating expectations of HK$1.001. Following the earnings report the stock price went up 2.634%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$271.37 (20.08% Upside)
HK$271.37 (20.08% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BeOne Medicines Ltd
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
6160 Stock 12 Month Forecast
Average Price Target
HK$271.37
▲(20.08% Upside)
Technical Analysis
Innovent Biologics
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―